Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.50 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.50 |
| ▸ | PREP | P48147 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 4/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4635925 | 0.81 | DPP4 (0.47) | DPP4DPP8DPP9DPP7PREP | |
| SCHEMBL4635559 | 0.78 | DPP4 (0.47) | DPP4DPP8DPP9DPP7PREP | |
| SCHEMBL3532873 | 0.78 | NOTUM (0.48) | DPP4DPP8DPP9DPP7PREP | |
| SCHEMBL1963730 | 0.77 | DPP4 (0.56) | DPP4DPP8DPP9DPP7PREP | |
| SCHEMBL250177 | 0.77 | NOTUM (0.47) | DPP4DPP8DPP9DPP7PREP | |
| SCHEMBL4635419 | 0.76 | DPP4 (0.49) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL3222955 | 0.76 | HTR2C (0.55) | DPP4DPP8DPP9DPP7PREP | |
| SCHEMBL20830204 | 0.75 | DRD2 (0.49) | DPP4DPP8DPP9DPP7PREP | |
| SCHEMBL4635182 | 0.75 | DPP4 (0.50) | DPP4DPP8DPP9DPP7PREP | |
| SCHEMBL249912 | 0.74 | NOTUM (0.51) | DPP4HSD11B1TRPV4ARNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-04 | — | — | US | disclosed |
| EP-1931633-A2 | DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007029086-A2 | DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | DPP4, DPP3, DPP8 | DPP4 1/4885DPP8 3/4885DPP9 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.